A combination of imatinib and a BH3 mimetic may prove to be beneficial for resistant CML cells bearing mutations in BIM, but would seem ineffective on patients with lower levels of BAX, as BAK does not seem to compensate for the lack of BAX. The gene discussed is BAX; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.